Preradiotherapy MR Imaging: A prospective pilot study of the usefulness of performing an MR examination shortly before radiation therapy in patients with glioblastoma

dc.contributor.author
Majós Torró, Carlos
dc.contributor.author
Cos Domingo, Mònica
dc.contributor.author
Castañer, Sara
dc.contributor.author
Pons Escoda, Albert
dc.contributor.author
Gil Gil, Miguel
dc.contributor.author
Fernández Coello, Alejandro
dc.contributor.author
Macià, Miquel
dc.contributor.author
Bruna, Jordi
dc.contributor.author
Aguilera, Carles
dc.date.issued
2025-01-30T16:25:57Z
dc.date.issued
2025-01-30T16:25:57Z
dc.date.issued
2016-12-01
dc.date.issued
2025-01-30T16:25:58Z
dc.identifier
0195-6108
dc.identifier
https://hdl.handle.net/2445/218245
dc.identifier
689783
dc.identifier
27609621
dc.description.abstract
Background and purpose: Current protocols in patients with glioblastoma include performing an MR examination shortly after surgery and then 2-6 weeks after ending concomitant chemoradiotherapy. The assessment of this first postradiotherapy examination is challenging because the pseudoprogression phenomenon may appear. The aim of this study was to explore if performing an MR examination shortly before radiation therapy (preradiotherapy MR imaging) could improve the radiologic assessment of patients with glioblastoma. Materials and methods: A preradiotherapy MR imaging examination was prospectively performed before the start of radiation therapy in 28 consecutive patients with glioblastoma who had undergone surgical resection. Tumor response to chemoradiotherapy was assessed twice: With the early postoperative MR examination as baseline and with the preradiotherapy MR imaging examination as baseline. In addition, tumor growth in the preradiotherapy MR imaging examination was evaluated, and its correlation with patient survival was assessed with Kaplan-Meier analysis and Cox regression. Results: Tumor progression after radiation therapy was found in 16 patients, corresponding to pseudoprogression in 7 of them (44%). Four assessments of pseudoprogression switched to partial response or stable disease when preradiotherapy MR imaging was the baseline examination, and the ratio of pseudoprogression was reduced to 25% (3 of 12). Significant differences in survival were found when patients were stratified according to the pattern of tumor growth on preradiotherapy MR imaging (median overall survival "no-growth," 837 days; "focal-growth," 582 days; "global-growth," 344 days; P = .001). Conclusions: Performing a preradiotherapy MR imaging examination may improve the clinical management of patients with glioblastoma by reducing the ratio of pseudoprogression assessments and providing prognostic information.
dc.format
7 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Lippincott, Williams & Wilkins
dc.relation
Reproducció del document publicat a: https://doi.org/10.3174/ajnr.A4917
dc.relation
American Journal of Neuroradiology, 2016, vol. 37, num.12, p. 2224-2230
dc.relation
https://doi.org/10.3174/ajnr.A4917
dc.rights
(c) Lippincott, Williams & Wilkins, 2016
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Adults
dc.subject
Imatges per ressonància magnètica
dc.subject
Tumors cerebrals
dc.subject
Adulthood
dc.subject
Magnetic resonance imaging
dc.subject
Brain tumors
dc.title
Preradiotherapy MR Imaging: A prospective pilot study of the usefulness of performing an MR examination shortly before radiation therapy in patients with glioblastoma
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.